miRagen Therapeutics and Collaborators Identify Critical Role of microRNA-15 in Cardiomyogenesis

7/26/2011 8:42:12 AM

BOULDER, Colo.--(BUSINESS WIRE)--miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that new preclinical data published in the online edition of Circulation Research suggests that microRNA-15 (miR-15) inhibits cardiomyogenesis, the process whereby new heart muscle cells are formed. The research, exclusively licensed by miRagen Therapeutics, was conducted by researchers at the University of Texas Southwestern Medical Center, Washington University Center for Pharmacogenomics and miRagen.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• miRagen Therapeutics

• Clinical - Pre-Clinical